Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Vijay Subramaniam

Pulmonary Disease Williamsburg, VA Medical Doctor

NPI 1962510370 CMS profile 88490

5424 Discovery Park Blvd, Ste 204, Williamsburg, VA 23188

Open in the dashboard

General payments

$227,740

138 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,031,811 paid to institutions, not to them · program years 2019–2024

Through program year 2023, Vijay Subramaniam of Williamsburg, VA is reported in the CMS Open Payments database as having received $227,740 across 138 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,031,811 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $80 1
2022 General $157,237 26
2021 General $4,050 10
2020 General $19,185 26
2019 General $47,189 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vijay Subramaniam
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Vijay Subramaniam were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Vijay Subramaniam Pulmonary Disease median Middle half National median
2019 $47,189 $377 $109–$1,340 $163
2020 $19,185 $230 $56–$907 $114
2021 $4,050 $269 $68–$1,072 $132
2022 $157,237 $390 $100–$1,457 $149
2023 $80 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. United Therapeutics Corporation $157,409 23 payments
  2. GlaxoSmithKline, LLC. $63,036 54 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $5,866 14 payments
  4. Shionogi Inc $448 6 payments
  5. Grifols USA, LLC $264 10 payments
  6. AstraZeneca Pharmaceuticals LP $209 10 payments
  7. Amgen Inc. $91 4 payments
  8. Actelion Pharmaceuticals US, Inc. $80 1 payment
  9. Pulmonx Corporation $79 2 payments
  10. Resmed Corp $43 2 payments
  11. Other $216 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $162,003 22 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $60,490 27 payments
  3. Travel and Lodging $3,125 17 payments
  4. Food and Beverage $2,006 69 payments
  5. Education $117 3 payments
Products named General payments · program years 2019–2023
  1. TRELEGY ELLIPTA $59,385 50 payments
  2. OFEV $5,894 15 payments
  3. ANORO $3,653 3 payments
  4. TYVASO $959 3 payments
  5. Prolastin-C Liquid $264 10 payments
  6. AIMOVIG $113 5 payments
  7. UPTRAVI $80 1 payment
  8. OPSUMIT $80 1 payment
  9. CHARTIS CATHETER $79 2 payments
  10. ZEPHYR ENDOBRONCHIAL VALVE $79 2 payments
  11. Other $554 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record